Novartis subsidiary Alcon has secured approval from the US Food and Drug Administration (FDA) for its AcrySof IQ ReSTOR +3.0D multifocal toric intraocular lens (IOL).

The new IOL has been designed to address presbyopia and pre-existing corneal astigmatism at the time of cataract surgery in adult patients who require good near, intermediate and distance vision with an increased potential for spectacle independence.

Alcon is already marketing its AcrySof IOL in the European Union, Australia and Canada, as well as multiple countries in Central and South America and Asia.

The company intends to commercialize AcrySof IOL in the US on a rolling basis beginning in the first quarter of next year.

Astigmatism is a variation in the shape or curvature of the cornea that will cause blurred vision at all distances, while Presbyopia is an eye condition that happens as part of natural aging.

Alcon North America region president Sergio Duplan said: "The AcrySof IQ ReSTOR +3.0D Multifocal Toric IOL is an important addition to our market-leading IOL portfolio, and broadens our offering of presbyopia- and astigmatism-correcting lenses to meet the different visual needs of patients.

"We are committed to delivering ongoing innovation that enables surgeons to provide the best possible outcome for their patients."

Alcon produces eye care products for the treatment of conditions such as cataracts, glaucoma, retinal diseases and refractive errors.